PT  - JOURNAL ARTICLE
AU  - Borremans Benny
AU  - Gamble Amandine
AU  - KC Prager
AU  - K Helman Sarah
AU  - M McClain Abby
AU  - Cox Caitlin
AU  - Savage Van
AU  - James O Lloyd-Smith
TI  - Quantifying antibody kinetics and RNA shedding during early-phase SARS-CoV-2 infection
AID  - 10.1101/2020.05.15.20103275
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.15.20103275
4099  - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20103275.short
4100  - http://medrxiv.org/content/early/2020/05/20/2020.05.15.20103275.full
AB  - Our ability to understand and mitigate the spread of SARS-CoV-2 depends largely on antibody and viral RNA data that provide information about past exposure and shedding. Five months into the outbreak there is an impressive number of studies reporting antibody kinetics and RNA shedding dynamics, but extensive variation in detection assays, study group demographics, and laboratory protocols has presented a challenge for inferring the true biological patterns. Here, we combine existing data on SARS-CoV-2 IgG, IgM and RNA kinetics using a formal quantitative approach that enables integration of 3,214 data points from 516 individuals, published in 22 studies. This allows us to determine the mean values and distributions of IgG and IgM seroconversion times and titer kinetics, and to characterize how antibody and RNA detection probabilities change during the early phase of infection. We observe extensive variation in antibody response patterns and RNA detection patterns, explained by both individual heterogeneity and protocol differences such as targeted antigen and sample type. These results provide a robust reference for clinical management of individual patients, and a foundation for the mathematical models and serological surveys that underpin public health policies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBB was supported by the European Commission Horizon 2020 Marie Sklodowska-Curie Actions (grant no. 707840). JOL-S and AG are supported by the Defense Advanced Research Projects Agency DARPA PREEMPT # D18AC00031 and the UCLA AIDS Institute and Charity Treks, and JOL-S and KCP are supported by the U.S. National Science Foundation (DEB-1557022), the Strategic Environmental Research and Development Program (SERDP, RC-2635) of the U.S. Department of Defense and the Cooperative Ecosystem Studies Unit Cooperative Agreement #W9132T1920006.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available as Supplementary Information